Location History:
- Price, UT (US) (2007)
- Gaithersburg, MD (US) (2002 - 2014)
- Middletown, MD (US) (2005 - 2015)
Company Filing History:
8 out of 8,684 
1 out of 832,761 Years Active: 2002-2015
Title: **Innovator Spotlight: Mark A. Olson**
Introduction
Mark A. Olson, an inventor based in Gaithersburg, Maryland, has made significant contributions to the fields of immunology and toxin research. With a remarkable portfolio of nine patents, Olson has demonstrated his expertise by developing innovative solutions aimed at addressing serious health concerns, including ricin intoxication.
Latest Patents
Among his latest patents, Olson has developed a ricin vaccine that includes engineered disulfide bond polypeptides known as (SS)RTA. These polypeptides maintain the immunological properties of the wild type RTA while exhibiting none, or significantly reduced, N-glycosidase activity. This innovation enhances solubility and thermal stability, while decreasing the self-aggregation tendency compared to traditional RTA variants. Furthermore, his patent discloses methods for immunizing against ricin intoxication, providing critical tools for treating and preventing the effects of this potent toxin.
In addition, Olson has worked on bacterial superantigen vaccines. His invention encompasses genetically attenuated superantigen toxins that maintain the ability to elicit an immune response without the harmful attributes typically associated with superantigens. The effectiveness of these altered toxins has been demonstrated in protecting animals from challenges posed by wild type toxins, showcasing Olson's innovative approach to vaccine development.
Career Highlights
Throughout his career, Mark A. Olson has been associated with esteemed institutions, including the United States Army. His focus has primarily been on crafting advanced medical solutions through extensive research and development. His contributions to the field have not only enhanced scientific knowledge but have also provided practical applications for immunization against hazardous toxins.
Collaborations
Olson's impactful work has often involved collaboration with esteemed colleagues, including Sina Bavari and Robert G. Ulrich. These partnerships have been instrumental in furthering research and innovation, leading to groundbreaking advancements in vaccine technology and immunology.
Conclusion
Mark A. Olson's dedication to advancing medical science through innovative inventions has positioned him as a leading inventor in the field. With nine patents to his name, including significant advancements in ricin vaccines and superantigen toxins, his work continues to pave the way for improved healthcare solutions. As research evolves, the contributions of inventors like Olson will remain crucial in combating public health threats and advancing immunological research.